GlassScriptPhysician profile
Thien-An Hoang
NPI 1871792796
$1,591.46
in general payments reported to CMS, 2019-2025
20 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.80 · 2020: $158 · 2021: $52.23 · 2022: $155 · 2023: $273 · 2024: $472 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,183.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $188.76 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $187.19 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $178.65 | 2019-2025 | |
| Abbvie INC. | $140.05 | 2022-2023 | |
| Glaxosmithkline, LLC. | $135.45 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.50 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $104.86 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $97.52 | 2022-2025 | Spravato |
| Ascensia Diabetes Care US INC. | $79.60 | 2020 | |
| Exact Sciences Corporation | $74.34 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $66.04 | 2022-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $59.45 | 2024-2025 | Airsupra, Farxiga |
| Kowa Pharmaceuticals America, INC. | $28.75 | 2025 | Zoryve |
| Amarin Pharma, INC. | $27.67 | 2020 | |
| Dexcom, INC. | $27.59 | 2025 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $24.00 | 2023 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $21.44 | 2023 | Eliquis |
| Esperion Therapeutics, INC. | $15.99 | 2020 | |
| Nevro Corp. | $14.17 | 2022 | |
| Sumitomo Pharma America, INC. | $13.44 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thien-An Hoang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.